Pharmaceutical company AbbVie (ABBV) is drawing attention for its attractive dividend yield of 3.38%, significantly higher than the S&P 500 average of 1.1%. This strong yield positions AbbVie as a compelling option for income-seeking investors, especially given its history of consistent dividend growth—over 330% since its spin-off from Abbott Laboratories in 2013 and an impressive 25 years of annual increases when combined with Abbott’s record.
For investors aiming for $10,000 in annual dividend income, purchasing approximately 1,445 shares at around $205 each would require an investment of nearly $296,225. However, AbbVie’s strong growth trajectory—averaging annual gains of 16.2% over the past decade—and a robust pipeline of over 90 drugs in development enhance its appeal beyond just dividends. The stock’s forward P/E ratio of 14 suggests it remains reasonably priced relative to its historical average.
In summary, AbbVie stands out as a solid investment choice for those prioritizing dividend income while also seeking growth potential, making it a noteworthy consideration for portfolio diversification.
Source: fool.com